/ WHO WE ARE
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
8
FUNDS
Since 2000
/ EXPERT INSIGHT
RiverVest’s latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease.
/ CASE STUDY
RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex, Inc. in 2022 for $170 million plus additional milestone payments.
/ EXPERT INSIGHT
By Niall O’Donnell, Ph.D.
(June 14, 2023) – In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation.
/ FEATURED NEWS
ST. LOUIS (September 7, 2022) – Good Therapeutics – a RiverVest Venture Fund IV portfolio company – has entered into a definitive merger agreement to be acquired by…
28
COMMERCIAL PRODUCTS
Currently Treating Patients
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2023 RiverVest® All Rights Reserved. | Privacy Policy
Subscribe to our newsletter